GPHA President Jaeger Keynotes Lehman Investment Conference March 31
This article was originally published in The Pink Sheet Daily
Executive Summary
GPHA priorities of follow-on biologics, “authorized” generics are likely to be highlighted. CMS’ Trysla gives opening address at March 30-April 1 investment conference in Miami Beach.
You may also be interested in...
GPhA's 2005 Priorities Include Generic Biologics, Biodefense Incentives
The Generic Pharmaceutical Association will continue to push for an approval pathway for generic biologics and work against "authorized" generics and patent term exclusivity extensions contained in biodefense legislation, President Jaeger tells group's annual meeting.
Top Seven Pink Sheet Infographics Of 2023
A visual perspective on key regulatory topics in 2023, from clinical trial diversity to product approval trends and Medicare drug price negotiation.
Pink Sheet’s Top Seven Infographics Of 2022
From US drug pricing to Japan’s Sakigake expedited pathway, important regulatory developments and trends are easier to understand and track with Pink Sheet graphics.